BC Innovations | Apr 18, 2019
Translation in Brief

Agenus scales the AI ALPS

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data....
BC Week In Review | Feb 1, 2019
Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...
BC Extra | Jan 29, 2019
Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is the first of its...
BC Week In Review | May 18, 2018
Clinical News

Agenus shifts focus to cervical cancer from first-line NSCLC

Agenus Inc. (NASDAQ:AGEN) said in its 1Q18 earnings report that it shifted its developmental strategy to first seek approval of its checkpoint inhibitors as a second-line treatment for cervical cancer instead of as a first-line...
BC Week In Review | Jan 12, 2018
Company News

HealthCare Royalty in vaccine royalty deal with Agenus

Agenus Inc. (NASDAQ:AGEN) will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million in cash,...
BC Week In Review | Apr 21, 2017
Clinical News

AGEN2034: Ph I/II started

Agenus began an open-label, U.S. Phase I/II trial evaluating AGEN2034 in about 75 patients. The dose-escalation Phase I portion will evaluate AGEN2034 in patients with metastatic or locally advanced solid tumors. The Phase II portion...
BC Extra | Feb 23, 2017
Company News

Agenus pointing to its checkpoint inhibitors

Agenus Inc. (NASDAQ:AGEN) is looking past the demise of its Prophage G-200 vaccine in brain cancer and pointing investors to upcoming milestones for its checkpoint inhibitor combinations. The company’s shares fell 16% on Wednesday after...
Items per page:
1 - 7 of 7